Clinical Characteristics and Current Treatment of Age-Related Macular Degeneration
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Age-related macular degeneration (AMD) is a multifactorial degeneration of photoreceptors and retinal pigment epithelium. The societal impact is significant, with more than 2 million individuals in the United States alone affected by advanced stages of AMD. Recent progress in our understanding of this complex disease and parallel developments in therapeutics and imaging have translated into new management paradigms in recent years. However, there are many unanswered questions, and diagnostic and prognostic precision and treatment outcomes can still be improved. In this article, we discuss the clinical features of AMD, provide correlations with modern imaging and histopathology, and present an overview of treatment strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
Ranibizumab and bevacizumab for neovascular age-related macular degeneration
(2011) · New England Journal of Medicine · doi:10.1056/nejmoa1102673 · Cited by 2,669
Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration
Heier, J. S., Brown, D. M., Chong, V., Korobelnik, J.-F., Kaiser, P. K., Nguyen, Q. D., Kirchhof, B., Ho, A., Ogura, Y., Yancopoulos, G. D., et al. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.09.006 · Cited by 2,485 · cited 2×
“…after the results of the VIEW 1 and VIEW 2 studies, which were two parallel phase III trials that randomized 2419 patients to 0.5 mg monthly aflibercept, 2.0 mg monthly aflibercept, 2.0 mg aflibercept every 2 mo after three initial monthly doses, or monthly 0.5 mg ranibizumab (Heier et al. 2012).”
BackgroundInfluentialPegaptanib for neovascular age-related macular degeneration
Gragoudas, E. S., Adamis, A. P., Cunningham, E. T., Feinsod, M., & Guyer, D. R. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa042760 · Cited by 2,337 · cited 2×
“Pegaptanib became the first anti-VEGF agent approved by the FDA for treatment of neovascular AMD based on the VISION studies (Gragoudas et al. 2004) which demonstrated that pegaptanib 0.3 mg given intravitreally every 6 wk resulted in 70% of patients losing fewer than 15 letters of visual acuity,…”
BackgroundInfluentialPrevalence of age-related maculopathy
Klein, R., Klein, B. E. K., & Linton, K. L. P. (1992) · Ophthalmology · doi:10.1016/s0161-6420(92)31871-8 · Cited by 1,845 · cited 1×
“Several small, well-defined drusen will usually be present in the elderly (Klein et al. 1992).”
BackgroundRanibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration
Martin, D. F., Maguire, M. G., Fine, S. L., Ying, G.-S., Jaffe, G. J., Grunwald, J. E., Toth, C., Redford, M., & Ferris, F. L. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.03.053 · Cited by 1,715
Embryonic stem cell trials for macular degeneration: a preliminary report
Schwartz, S. D., Hubschman, J.-P., Heilwell, G., Franco-Cardenas, V., Pan, C. K., Ostrick, R. M., Mickunas, E., Gay, R., Klimanskaya, I., & Lanza, R. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60028-2 · Cited by 1,409
Brown, D. M., Michels, M., Kaiser, P. K., Heier, J. S., Sy, J. P., & Ianchulev, T. (2009) · Ophthalmology · doi:10.1016/j.ophtha.2008.10.018 · Cited by 1,318
Current concepts in the pathogenesis of age-related macular degeneration
Zarbin, M. A. (2004) · Archives of Ophthalmology · doi:10.1001/archopht.122.4.598 · Cited by 1,006 · cited 1×
“In a subset of individuals, these changes progress to more pathologically significant findings and manifest clinically as AMD (Zarbin 2004).”
BackgroundAgeing and degeneration in the macular region: A clinico-pathological study
Sarks, S. H. (1976) · British Journal of Ophthalmology · doi:10.1136/bjo.60.5.324 · Cited by 891 · cited 1×
“BLamD are uniformly seen by the seventh decade of life (Sarks 1976) and are composed of lipoproteins and amyloid b.”
Background(2001) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(01)00967-9 · Cited by 814
Racial Differences in the Cause-Specific Prevalence of Blindness in East Baltimore
Sommer, A., Tielsch, J. M., Katz, J., Quigley, H. A., Gottsch, J. D., Javitt, J. C., Martone, J. F., Royall, R. M., Witt, K. A., & Ezrine, S. (1991) · New England Journal of Medicine · doi:10.1056/nejm199111143252004 · Cited by 764 · cited 1×
“In the Baltimore Eye Study (BES), 30% of bilateral blindness was caused by AMD in Caucasians, whereas none of the African Americans became bilaterally blind from AMD (Sommer et al. 1991).”
BackgroundDICER1 loss and Alu RNA induce age-related macular degeneration via the NLRP3 inflammasome and MyD88
Tarallo, V., Hirano, Y., Gelfand, B. D., Dridi, S., Kerur, N., Kim, Y., Cho, W. G., Kaneko, H., Fowler, B. J., Bogdanovich, S., et al. (2012) · Cell · doi:10.1016/j.cell.2012.03.036 · Cited by 592 · cited 2×
“Inflammasomes are multiprotein complexes that activate inflammatory cascades, and have been identified as potential targets for both nonneovascular (Tarallo et al. 2012) and neovascular (Doyle et al. 2012) AMD.”
BackgroundKoh, A., Lee, W. K., Chen, L.-J., Chen, S.-J., Hashad, Y., Kim, H., Lai, T. Y., Pilz, S., Ruamviboonsuk, P., Tokaji, E., et al. (2012) · Retina · doi:10.1097/iae.0b013e31824f91e8 · Cited by 587 · cited 3×
“Combining PDTwith anti-VEGF agents appears to be an effective approach (Kim and Yu 2011; Koh et al. 2012; Lee et al. 2012b; Tomita et al. 2012).”
BackgroundMethodInfluentialRisk factors for neovascular age-related macular degeneration
(1992) · Archives of Ophthalmology · doi:10.1001/archopht.1992.01080240041025 · Cited by 486
Hypertension, cardiovascular disease, and age-related macular degeneration
Hyman, L. (2000) · Archives of Ophthalmology · doi:10.1001/archopht.118.3.351 · Cited by 441
A prospective study of cigarette smoking and age-related macular degeneration in women
Seddon, J. M. (1996) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1996.03540140029022 · Cited by 435
Argon Laser Photocoagulation for Senile Macular Degeneration: Results of a Randomized Clinical Trial
(1982) · Archives of Ophthalmology · doi:10.1001/archopht.1982.01030030920003 · Cited by 405
FACTORS ASSOCIATED WITH AGE-RELATED MACULAR DEGENERATION
GOLDBERG, J., FLOWERDEW, G., SMITH, E., BRODY, J. A., & TSO, M. O. M. (1988) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a115023 · Cited by 384 · cited 2×
“A larger number of epidemiological studies have implicated hypertension as a risk factor (Sperduto and Hiller 1986; Goldberg et al. 1988; Hyman et al. 2000; Klein et al. 2003; van Leeuwen et al. 2003) compared to those that did not (Eye-Disease-CaseControl-Study-Group 1992; Klein et al. 1993).”
BackgroundA Prospective Study of Cigarette Smoking and Risk of Age-Related Macular Degeneration in Men
Christen, W. G. (1996) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1996.03540140035023 · Cited by 320
Yehoshua, Z., Alexandre de Amorim Garcia Filho, C., Nunes, R. P., Gregori, G., Penha, F. M., Moshfeghi, A. A., Zhang, K., Sadda, S., Feuer, W., & Rosenfeld, P. J. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2013.09.044 · Cited by 299 · cited 1×
“(Garcia Filho et al. 2014; Yehoshua et al. 2014).”
(2004) · Ophthalmology · doi:10.1016/j.ophtha.2004.07.023 · Cited by 279 · cited 2×
“Patients with predominantly hemorrhagic PEDs often present with poor visual acuity (Bressler et al. 2004).”
BackgroundSarks, S., Cherepanoff, S., Killingsworth, M., & Sarks, J. (2007) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.06-0443 · Cited by 244
The association of cardiovascular disease with the long-term incidence of age-related maculopathy
Klein, R., Klein, B. E. K., Tomany, S. C., & Cruickshanks, K. J. (2003) · Ophthalmology · doi:10.1016/s0161-6420(03)00599-2 · Cited by 209
BRESSLER, N. M., SILVA, J. C., BRESSLER, S. B., FINE, S. L., & GREEN, W. R. (1994) · Retina · doi:10.1097/00006982-199414020-00006 · Cited by 200 · cited 1×
“In AMD with RPE degeneration, the patchy BLamD seen in normal aging develop an overlying layer of a diffuse, thick, amorphous, hyalinized material, which can become nodular elevations (Bressler et al. 1994).”
BackgroundCukras, C., Agrón, E., Klein, M. L., Ferris, F. L., Chew, E. Y., Gensler, G., & Wong, W. T. (2010) · Ophthalmology · doi:10.1016/j.ophtha.2009.12.002 · Cited by 170
Mata, N. L., Lichter, J. B., Vogel, R., Han, Y., Bui, T. V., & Singerman, L. J. (2013) · Retina · doi:10.1097/iae.0b013e318265801d · Cited by 157 · cited 1×
“Early trials indicate that visual cycle modulators may have a role in slowing the progression of geographic atrophy (Kubota et al. 2012; Mata et al. 2013).”
Background
Cited by
Efficacy and Safety of Abicipar in Neovascular Age-Related Macular Degeneration
Kunimoto, D., Yoon, Y. H., Wykoff, C. C., Chang, A., Khurana, R. N., Maturi, R. K., Agostini, H., Souied, E., Chow, D. R., Lotery, A. J., et al. (2020) · Ophthalmology · doi:10.1016/j.ophtha.2020.03.035 · Cited by 91
Targeting MAPK Signaling in Age-Related Macular Degeneration
Kyosseva, S. V. (2016) · Ophthalmology and Eye Diseases · doi:10.4137/oed.s32200 · Cited by 74
Callanan, D., Kunimoto, D., Maturi, R. K., Patel, S. S., Staurenghi, G., Wolf, S., Cheetham, J. K., Hohman, T. C., Kim, K., López, F. J., et al. (2018) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2018.0062 · Cited by 73
“1 Characterization of the endothelial cell proliferative and vascular permeability effects of vascular endothelial growth factor (VEGF) led to the development of anti-VEGF treatments for nAMD.”
InfluentialMakarev, E., Cantor, C., Zhavoronkov, A., Buzdin, A., Aliper, A., & Csoka, A. B. (2014) · Aging · doi:10.18632/aging.100711 · Cited by 50
“epithelium (RPE) cells of the eye in older age [7].”
Background
Metadata
- Authors
- Yonekawa, Y., & Kim, I. K.
- Venue
- Cold Spring Harbor Perspectives in Medicine
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2014-10-03
- Volume
- 5
- Issue
- 1
- Pages
- a017178-a017178
- ISSN
- 2157-1422 (ISSN-L)
- OpenAlex
- W2127843105
- Cited by
- 73
- References
- 29
- Type
- posted content
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.